White paper
The Inflation Reduction Act (IRA) and its implications for intellectual property incentives to develop drugs for select populations
The pharmaceutical industry has long thrived on strong intellectual property (IP) incentives, driving groundbreaking drug development that extends life expectancy, cures diseases, and fuels the global economy. However, the Inflation Reduction Act (IRA) introduces new Medicare drug price negotiation provisions that could disrupt this delicate balance.
This white paper examines the historical role of IP laws in fostering innovation for critical populations, including those with rare diseases, pediatric patients, and those relying on generic medicines. It also explores how IRA’s pricing policies may deter investment in life-saving research and hinder initiatives like the Cancer Moonshot and pandemic preparedness. Finally, the paper offers insights into potential legislative adjustments that could sustain innovation while preserving the government’s role in drug pricing negotiations.
Download the white paper to understand the future of pharmaceutical innovation in the wake of IRA.
*Available in English only
